Incyte to buy Vega Therapeutics for up to $2B, betting on a subcutaneous bleeding-disorder antibody still in trials

The deal hinges on VGA039, an investigational Protein S-modulating antibody now in a 60-patient Phase 3 crossover trial that has not yet reported results.

Incyte said on June 8 that it will acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal worth up to $2.0 billion. The structure is front-loaded: $1.25 billion in cash upfront, with up to $750 million more tied to sales milestones, according to the company’s announcement. The acquisition pushes Incyte’s hematology franchise into bleeding disorders for the first time.

The asset is VGA039, an investigational monoclonal antibody that, per the company, modulates Protein S — a natural anticoagulant — to improve hemostasis. Its lead indication is von Willebrand disease (VWD), which the company describes as the most common inherited bleeding disorder and says affects roughly 135,000 diagnosed patients in the United States. The pitch is convenience: VGA039 is dosed subcutaneously, against current factor-replacement prophylaxis that the company says can require two to three intravenous infusions a week.

A Phase 3 still gathering data

VGA039 sits in the Phase 3 VIVID-6 study (NCT07115004). Per ClinicalTrials.gov, it is an open-label, single-sequence crossover trial enrolling about 60 patients aged 12 to 75 with any VWD type and a historical annualized bleeding rate of at least 12. Patients undergo an observational period of at least 24 weeks before roughly 49 weeks of treatment; the primary endpoint is the incidence of bleeding events. The registry’s exclusion criteria are notable given the mechanism: patients with prothrombotic disorders or a history of arterial or venous thrombosis are barred — a reminder that the drug works by blunting a natural anticoagulant. The trial is recruiting, with completion projected for October 2028. No results have been posted.

Incyte CEO Bill Meury called VGA039 “a first-in-class, Phase 3 asset with compelling early data” — a characterization that no peer-reviewed efficacy data yet substantiate, and the trial registry confirms no results have been reported.

VGA039 holds FDA Breakthrough Therapy, Fast Track, orphan drug and rare pediatric disease designations. Incyte expects to close in the third quarter of 2026, pending Hart-Scott-Rodino clearance, and to book an R&D charge of about $1.25 billion.